TOCOMED: Vaginal Indomethacin for Preterm Labor

Sponsor
Hadassah Medical Organization (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04404686
Collaborator
Sheba Medical Center (Other), Soroka University Medical Center (Other)
300
2
54

Study Details

Study Description

Brief Summary

Indometacin is a cyclooxygenase agent from the NSAID family that has been used to treat preterm contractions since the 70's by preventing the synthesis of prostaglandins. It has been shown to be significantly more effective than placebo and postpone labor for 7-10 days, prolong pregnancies above 37 weeks of gestation and reduce numbers of small for gestational age neonates.

Nifedipine is a calcium channel blocker agent that has been shown to reduce rates of labor within 48 hours from treatment.

Previous studies comparing rectal Indometacin to oral nifedipine were inconclusive.

Prostaglandins are synthesized in the uterus and the uterine cervix and therefore local administration of Indometacin may be more effective than other forms of administration, as been shown in a previous study.

In this study we aim to compare vaginal Indometacin administration to a commonly used tocolytic agent, nifedipine.

Condition or Disease Intervention/Treatment Phase
Phase 2/Phase 3

Study Design

Study Type:
Interventional
Anticipated Enrollment :
300 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Masking Description:
Caregivers will receive a closed envelope with the drug to be used. since the routes of administration are different, from that point on the caregiver and patient will be aware of chosen drug
Primary Purpose:
Treatment
Official Title:
Vaginal Indomethacin Versus Oral Nifedipine for Preterm Labor; a Randomized Controlled Trial
Anticipated Study Start Date :
Oct 1, 2020
Anticipated Primary Completion Date :
Apr 1, 2024
Anticipated Study Completion Date :
Apr 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Indomethacin group

Group of patients receiving Indomethacin for preterm labor treatment.

Drug: Indomethacin
Per vagina administration of 100 mg followed by a second 100 mg dosage the following day
Other Names:
  • Indomed
  • Active Comparator: Nifedipine group

    Group of patients receiving Nifedipine for preterm labor treatment.

    Drug: Nifedipine
    Per os administration according to current protocol of 20mg each 20 minutes for 1 hour followed by 20 mg q8 for 48 hours.
    Other Names:
  • Pressolat
  • Outcome Measures

    Primary Outcome Measures

    1. Time to delivery [through study completion, approximately 1 year]

      The time from administration of intervention do delivery

    2. Gestational age [through study completion, approximately 1 year]

      Days from last menstrual period

    Secondary Outcome Measures

    1. Rate of preterm deliveries [through study completion, approximately 1 year]

      Rate of deliveries under 37+0/7 weeks of gestation

    2. Rate of remote from term deliveries [through study completion, approximately 1 year]

      Rate of deliveries under 34+0/7 weeks of gestation

    3. Rate of extreme preterm deliveries [through study completion, approximately 1 year]

      Rate of deliveries under 28+0/7 weeks of gestation

    4. neonatal immediate outcomes [through study completion, approximately 1 year]

      Neonatal Apgar scores

    5. Neonatal immediate outcome [through study completion, approximately 1 year]

      Neonatal umbilical cord pH levels

    6. Neonatal birth weight [through study completion, approximately 1 year]

      birth wight as recorded in chart in grams

    7. Neonatal outcomes [through study completion, approximately 1 year]

      neonatal intensive care unit administration rate

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    16 Years to 60 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Singe fetus

    • Gestational age between 24+0/7 and 31+6/7

    • At least one uterine contraction in ten minutes for at least 20 minutes upon tocography admission

    • Cervical parameters: 1 cm dilation or more or 80% cervical effacement or cervical length 20mm or less

    Exclusion Criteria:
    • Rupture of membranes

    • Vaginal bleeding

    • Cervical dilation ≥5cm

    • Known fetal malformations

    • Fetal heart rate abnormalities

    • Suspected placental abruption of adherent placental syndrome

    • Known sensitivity to one of the drugs used in the study (Indometacin and nifedipine)

    • Maternal hypotension and known aortic or mitral stenosis

    • Presence of cervical cerclage

    • Previous administration of tocolytic drugs in current pregnancy

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Hadassah Medical Organization
    • Sheba Medical Center
    • Soroka University Medical Center

    Investigators

    • Principal Investigator: Hila Hochler, MD, Hadassah Medical Organization

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Hila Hocler MD, Principal Investigator, Hadassah Medical Organization
    ClinicalTrials.gov Identifier:
    NCT04404686
    Other Study ID Numbers:
    • TOCOMED-HMO-CTIL
    First Posted:
    May 27, 2020
    Last Update Posted:
    Aug 11, 2020
    Last Verified:
    Aug 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Hila Hocler MD, Principal Investigator, Hadassah Medical Organization
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 11, 2020